Keyphrases
4-fold
25%
5-Flucytosine
100%
Amphotericin B
100%
Antifungal Susceptibility
100%
Basal Resistance
25%
Broth Microdilution
25%
Candida Albicans (C. albicans)
25%
Cerebrospinal Fluid
75%
Combination Therapy
25%
Concentration Ratio
50%
Cryptococcal Meningitis
50%
Cryptococcosis
25%
Cryptococcus
75%
Cryptococcus Isolates
25%
Cryptococcus Neoformans
100%
Drug Delivery System
25%
Early Fungicidal Activity
25%
Flucytosine
50%
Lipids
25%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
25%
MIC50
25%
MIC90
25%
Minimum Inhibitory Concentration
75%
Monotherapy
25%
Nanocrystals
25%
Novel Drug Delivery
25%
Oral Amphotericin B
50%
Randomized Clinical Trial
25%
Tandem Mass Spectrometry
25%
Uganda
50%
Ugandan
25%
Immunology and Microbiology
Antifungal Susceptibility
100%
Broth Dilution
33%
Candida Albicans
33%
Cerebrospinal Fluid
100%
Concentration Ratio
66%
Cryptococcus neoformans
100%
Filobasidiella
100%
Fungicidal Activity
33%
Human Immunodeficiency Virus
33%
Liquid Chromatography Mass Spectrometry
33%
Meningitis
66%
MIC50
33%
MIC90
33%
Minimum Inhibitory Concentration
100%
Tandem Mass Spectrometry
33%
Pharmacology, Toxicology and Pharmaceutical Science
Amphotericin
100%
Amphotericin B
100%
Candida Albicans
20%
Combination Therapy
20%
Cryptococcal Meningitis
40%
Cryptococcosis
20%
Cryptococcus neoformans
100%
Filobasidiella
60%
Flucytosine
100%
HIV
20%
Minimum Inhibitory Concentration
60%
Monotherapy
20%
Randomized Clinical Trial
20%
Medicine and Dentistry
Amphotericin
100%
Amphotericin B
100%
Antifungal Susceptibility
100%
Cerebrospinal Fluid
60%
Combination Therapy
20%
Cryptococcal Meningitis
40%
Cryptococcosis
20%
Flucytosine
100%
Fungicidal Activity
20%
Human Immunodeficiency Virus
20%
Liquid Chromatography-Mass Spectrometry
20%
Monotherapy
20%
Randomized Clinical Trial
20%
Tandem Mass Spectrometry
20%